Nasdaq Bear Market: 5 Exceptional Growth Stocks You'll Regret Not Buying On the DipThe Motley Fool • 08/20/22
Exelixis, Inc. (EXEL) CEO Michael Morrissey on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Exelixis Handily Beats Second-Quarter Expectations, Retains 2022 OutlookInvestors Business Daily • 08/09/22
Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 08/09/22
Nasdaq Bear Market: 5 Fantastic Growth Stocks You'll Regret Not Buying On the DipThe Motley Fool • 08/06/22
Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022Business Wire • 07/26/22
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney CancerBusiness Wire • 07/11/22
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer TherapiesBusiness Wire • 07/07/22
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus ConferenceBusiness Wire • 07/05/22
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal CancerBusiness Wire • 06/21/22